{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:18Z","timestamp":1792704858575,"version":"4.5.0"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pancreatic cancer is one of the most malignant tumors with increased incidence rate. The effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory. New treatment strategy such as immunotherapy need to be investigated. The accumulation of desmoplastic stroma, infiltration of immunosuppressive cells including myeloid derived suppressor cells (MDSCs), tumor associated macrophages (TAMs), cancer\u2010associated fibroblasts (CAFs), and regulatory T cells (Tregs), as well as tumor associated cytokine such as TGF-\u03b2, IL-10, IL-35, CCL5 and CXCL12 construct an immunosuppressive microenvironment of pancreatic cancer, which presents challenges for immunotherapy. In this review article, we explore the roles and mechanism of immunosuppressive cells and lymphocytes in establishing an immunosuppressive tumor microenvironment in pancreatic cancer. In addition, immunotherapy strategies for pancreatic cancer based on tumor microenvironment including immune checkpoint inhibitors, targeting extracellular matrix (ECM), interfering with stromal cells or cytokines in TME, cancer vaccines and extracellular vesicles (EVs) are also discussed. It is necessary to identify an approach of immunotherapy in combination with other modalities to produce a synergistic effect with increased response rates in pancreatic cancer therapy.<\/jats:p>","DOI":"10.3389\/fonc.2023.1166860","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T01:59:05Z","timestamp":1680055145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000288","article-title":"The pancreatic cancer microenvironment","volume":"23","author":"Dougan","year":"2017","journal-title":"Cancer J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1053\/j.gastro.2020.11.044","article-title":"Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice","volume":"160","author":"Peran","year":"2021","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","article-title":"Tumor microenvironment participates in metastasis of pancreatic cancer","volume":"17","author":"Ren","year":"2018","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4RI0515-204R","article-title":"Transcriptional regulation of myeloid-derived suppressor cells","volume":"98","author":"Condamine","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4601","article-title":"Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner","volume":"73","author":"Mace","year":"2013","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: Immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.09.039","article-title":"The stromal compartments in pancreatic cancer: are there any therapeutic targets","volume":"343","author":"Lunardi","year":"2014","journal-title":"Cancer Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.12.009","article-title":"Arginine metabolism in soft tissue sarcoma","volume":"61","author":"Yan","year":"2011","journal-title":"J Dermatol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellimm.2005.01.004","article-title":"L-arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes","volume":"232","author":"Zea","year":"2004","journal-title":"Cell Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive oxygen species as regulators of MDSC-mediated immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J Immunol"},{"key":"B22","article-title":"Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients","volume":"61","author":"Schmielau","year":"2001","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.psychres.2015.06.002","article-title":"Myeloid-derived suppressor cells in major depression patients suppress T-cell responses through the production of reactive oxygen species","volume":"228","author":"Wei","year":"2015","journal-title":"Psychiatry Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.07.003","article-title":"Myeloid-derived suppressor cells modulate b-cell responses","volume":"188","author":"Lelis","year":"2017","journal-title":"Immunol Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: The green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: Current progress and new prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850093","article-title":"The interplay between inflammation and stromal components in pancreatic cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.12.001","article-title":"Suppression of T cells by myeloid-derived suppressor cells in cancer","volume":"78","author":"Chen","year":"2017","journal-title":"Hum Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655152","article-title":"Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer","volume":"9","author":"Geng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.09.009","article-title":"Fibroblasts fuel immune escape in the tumor microenvironment","volume":"5","author":"De Jaeghere","year":"2019","journal-title":"Trends Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0125","article-title":"Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion","volume":"24","author":"Cho","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.273","article-title":"Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0507","article-title":"Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma","volume":"8","author":"Xiang","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0205","article-title":"Cancer-associated fibroblasts affect intratumoral CD8+ and FoxP3+ T cells Via IL6 in the tumor microenvironment","volume":"24","author":"Kato","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1319269111","article-title":"TGF-\u03b2-inducible microRNA-183 silences tumor-associated natural killer cells","volume":"111","author":"Donatelli","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906481106","article-title":"Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity","volume":"106","author":"Balsamo","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102756","article-title":"PD-1 expression by lymph node and intratumoral regulatory T cells is associated with lymph node metastasis in pancreatic cancer","volume":"12","author":"Seifert","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1451514","article-title":"FOXP3+ treg as a therapeutic target for promoting anti-tumor immunity","volume":"22","author":"Whiteside","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1027473","article-title":"IP-10\/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer","volume":"4","author":"Lunardi","year":"2015","journal-title":"Oncoimmunology"},{"key":"B48","article-title":"Changes of Th17\/Treg cell and related cytokines in pancreatic cancer patients","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm064","article-title":"Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma","volume":"99","author":"Nummer","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.molmed.2007.08.005","article-title":"TGFbeta1 and treg cells: alliance for tolerance","volume":"13","author":"Bommireddy","year":"2007","journal-title":"Trends Mol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.40","article-title":"Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells","volume":"177","author":"Kryczek","year":"2006","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00470.x","article-title":"Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer","volume":"98","author":"Nakamura","year":"2007","journal-title":"Cancer Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.01.031","article-title":"Tumor-associated macrophages","volume":"30","author":"Cassetta","year":"2020","journal-title":"Curr Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052662","article-title":"How macrophages become transcriptionally dysregulated: A hidden impact of antitumor therapy","volume":"22","author":"Medvedeva","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2018.03.009","article-title":"Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer","volume":"366","author":"Piao","year":"2018","journal-title":"Exp Cell Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ccell.2021.04.016","article-title":"The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth","volume":"39","author":"Dong","year":"2021","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14295","article-title":"Metabolism and TAM functions-it takes two to tango","volume":"285","author":"Mazzone","year":"2018","journal-title":"FEBS J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15726","article-title":"Tumor-associated macrophages in immunotherapy","volume":"288","author":"Yan","year":"2021","journal-title":"FEBS J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0479","article-title":"Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg\/Th17 cell imbalance in epithelial ovarian cancer","volume":"6","author":"Zhou","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12530","article-title":"Potential targeting of B7-H4 for the treatment of cancer","volume":"276","author":"Podojil","year":"2017","journal-title":"Immunol Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000308","article-title":"Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.01.001","article-title":"Targeting pancreatic stellate cells in cancer","volume":"5","author":"Schnittert","year":"2019","journal-title":"Trends Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2019.07.001","article-title":"The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets","volume":"48","author":"Farran","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110693","article-title":"Macrophages in pancreatitis: Mechanisms and therapeutic potential","volume":"131","author":"Hu","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26290","article-title":"High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer","volume":"130","author":"Tang","year":"2012","journal-title":"Int J Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.clinre.2015.05.018","article-title":"Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer","author":"Masamune","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.553967","article-title":"Tumor-associated neutrophils and macrophages-heterogenous but not chaotic","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib","volume":"150","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.10.013","article-title":"Unmasking the many faces of tumor-associated neutrophils and macrophages: Considerations for targeting innate immune cells in cancer","volume":"5","author":"Keeley","year":"2019","journal-title":"Trends Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol Aspects Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-230x(03)90004-2","article-title":"Natural killer cells and cancer","volume":"90","author":"Wu","year":"2003","journal-title":"Adv Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108374","article-title":"Crosstalk between macrophages and natural killer cells in the tumor microenvironment","volume":"101","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.it.2003.10.012","article-title":"NK cell and DC interactions","volume":"25","author":"Cooper","year":"2004","journal-title":"Trends Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2174\/092986712800099857","article-title":"The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions","volume":"19","author":"Jacobs","year":"2012","journal-title":"Curr Med Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.122","article-title":"Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective","volume":"7","author":"Mahmood","year":"2015","journal-title":"Immunotherapy"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-49270-0_9","article-title":"Mast cells in the tumor microenvironment","volume":"1273","author":"Aponte-L\u00f3pez","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1230","article-title":"Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression","volume":"16","author":"Strouch","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4479","article-title":"Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer","volume":"73","author":"Ma","year":"2013","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030330","article-title":"CAFs and TGF-\u03b2 signaling activation by mast cells contribute to resistance to Gemcitabine\/Nabpaclitaxel in pancreatic cancer","volume":"11","author":"Porcelli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2623","article-title":"PI3K\/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer","volume":"19","author":"Khan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008922","article-title":"Mast cells mobilize myeloid-derived suppressor cells and treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model","volume":"5","author":"Yang","year":"2010","journal-title":"PloS One"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: Markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2170-8","article-title":"How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions","volume":"68","author":"Bruger","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B89","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41467-019-14134-w","article-title":"Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms","volume":"11","author":"Pelon","year":"2020","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1742-0","article-title":"Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma","volume":"64","author":"Takahashi","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discovery"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32278","article-title":"Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S291767","article-title":"Fibroblast activation protein (FAP)-targeted CAR-T cells: Launching an attack on tumor stroma","volume":"10","author":"Bughda","year":"2021","journal-title":"Immunotargets Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2033","article-title":"Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein (FAP) synergizes with antitumor vaccine therapy in mice","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819889116","article-title":"Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy","volume":"116","author":"Chauhan","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B100","doi-asserted-by":"publisher","first-page":"17444","DOI":"10.1038\/s41598-020-74368-3","article-title":"The vitamin d analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity","volume":"10","author":"Gorchs","year":"2020","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02734-2","article-title":"Cancer-associated fibroblasts in colorectal cancer","volume":"24","author":"Kamali Zonouzi","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.09.002","article-title":"Repurposing vitamin d for treatment of human malignancies via targeting tumor microenvironment","volume":"9","author":"Wu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/nu13061987","article-title":"Vitamin d supplementation regulates postoperative serum levels of PD-L1 in patients with digestive tract cancer and improves survivals in the highest quintile of PD-L1: A Post hoc analysis of the AMATERASU randomized controlled trial","volume":"13","author":"Morita","year":"2021","journal-title":"Nutrients"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discovery"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/bs.ircmb.2019.07.008","article-title":"Interplay between dendritic cells and cancer cells","volume":"348","author":"Martinek","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic cell regulation of T helper cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2212","article-title":"An immunosuppressive dendritic cell subset accumulates at secondary sites and promotes metastasis in pancreatic cancer","volume":"77","author":"Kenkel","year":"2017","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212339","article-title":"Dendritic cells and cancer immunotherapy: The adjuvant effect","volume":"22","author":"Nava","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1875638","article-title":"Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer","volume":"10","author":"Yang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1510-y","article-title":"Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and b-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model","volume":"63","author":"Bauer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B119","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cas.12621","article-title":"Phase I pilot study of wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer","volume":"106","author":"Mayanagi","year":"2015","journal-title":"Cancer Sci"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0489-2","article-title":"Maturation of monocyte-derived dendritic cells with toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration","volume":"57","author":"Boullart","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1218-4","article-title":"Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously","volume":"61","author":"Zhang","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1126\/science.1249481","article-title":"Cancer immunotherapy","volume":"342","author":"McNutt","year":"2013","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: A phase ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"B124","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest New Drugs"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu205","article-title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1078-0432.CCR-19-1635","article-title":"Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy","volume":"26","author":"Sharma","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br J Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000587","article-title":"Randomized phase II study of the bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer","volume":"8","author":"Overman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15034104","article-title":"Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma","volume":"15","author":"Karakhanova","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/BF01526207","article-title":"Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of c-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity","volume":"38","author":"Scheid","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-011-0159-0","article-title":"A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer","volume":"12","author":"Rong","year":"2012","journal-title":"Clin Exp Med"},{"key":"B137","article-title":"Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes","volume":"28","author":"Kondo","year":"2008","journal-title":"Anticancer Res"},{"key":"B138","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0314","article-title":"Treatment with chemotherapy and dendritic cells pulsed with multiple wilms' tumor 1 (WT1)-specific MHC class I\/II-restricted epitopes for pancreatic cancer","volume":"20","author":"Koido","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-017-0459-2","article-title":"Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer","volume":"10","author":"Mehrotra","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.03.018","article-title":"Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer","volume":"186","author":"Lin","year":"2017","journal-title":"Immunol Lett"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2513-4","article-title":"Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III\/IV) pancreatic cancer: a promising treatment","volume":"143","author":"Lin","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169736","article-title":"Clinical and immune effects of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"12","author":"Ullenhag","year":"2017","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2520","article-title":"Molecular pathways: Activating T cells after cancer cell phagocytosis from blockade of CD47 \"Don't eat me\" signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.01.004","article-title":"Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis","volume":"121","author":"Koh","year":"2017","journal-title":"Biomaterials"},{"key":"B147","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biomaterials.2016.09.031","article-title":"Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA","volume":"111","author":"Morishita","year":"2016","journal-title":"Biomaterials"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00851.x","article-title":"Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70","volume":"14","author":"Xie","year":"2010","journal-title":"J Cell Mol Med"},{"key":"B149","article-title":"Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes","volume":"3","author":"Hao","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J Transl Med"},{"key":"B151","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41467-018-02865-1","article-title":"Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells","volume":"9","author":"Seo","year":"2018","journal-title":"Nat Commun"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101988","article-title":"Immune surveillance properties of human NK cell-derived exosomes","volume":"189","author":"Lugini","year":"2012","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.007","article-title":"Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node","volume":"25","author":"Cheng","year":"2017","journal-title":"Mol Ther"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"B155","article-title":"AstraZeneca","volume-title":"Study of tremelimumab in patients with advanced solid tumors","year":""},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"B157","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.7150\/thno.51383","article-title":"Targeting transforming growth factor-\u03b2 signaling for enhanced cancer chemotherapy","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discovery"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.135","article-title":"Dendritic cell-based vaccination in solid cancer","volume":"21","author":"Stift","year":"2003","journal-title":"J Clin Oncol"},{"key":"B162","article-title":"Long-term outcome of immunotherapy for patients with refractory pancreatic cancer","volume":"29","author":"Nakamura","year":"2009","journal-title":"Anticancer Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"9869","DOI":"10.1038\/s41598-018-28238-8","article-title":"1-Methyl-D-tryptophan reduces tumor CD133+ cells, wnt\/\u03b2-catenin and NF-\u03ba\u03b2p65 while enhances lymphocytes NF-\u03ba\u03b22, STAT3, and STAT4 pathways in murine pancreatic adenocarcinoma","volume":"8","author":"Alahdal","year":"2018","journal-title":"Sci Rep"},{"key":"B164","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12951-022-01382-0","article-title":"Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment","volume":"20","author":"Li","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080267","article-title":"Extracellular vesicles (EVs) and pancreatic cancer: From the role of EVs to the interference with EV-mediated reciprocal communication","volume":"8","author":"Moeng","year":"2020","journal-title":"Biomedicines"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01456","article-title":"Extracellular vesicle-dependent cross-talk in cancer-focus on pancreatic cancer","volume":"10","author":"Nannan","year":"2020","journal-title":"Front Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060874","article-title":"Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201901779","article-title":"Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy","volume":"6","author":"Xie","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040373","article-title":"Pancreatic cancer signaling pathways, genetic alterations, and tumor microenvironment: The barriers affecting the method of treatment","volume":"9","author":"Javadrashid","year":"2021","journal-title":"Biomedicines"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-14-1591","article-title":"Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer","volume":"21","author":"Alagesan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK inhibition: A new front in the war against MAPK pathway-driven cancers","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Discovery"},{"key":"B173","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09367-9","article-title":"Landmark series: Immunotherapy and targeted therapy for pancreatic cancer","volume":"28","author":"Rocha","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for pancreatic cancer: A 2020 update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1166860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T01:59:10Z","timestamp":1680055150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1166860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":176,"alternative-id":["10.3389\/fonc.2023.1166860"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1166860","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"article-number":"1166860"}}